---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-24-032080"
form_type: "8-K"
ticker: "RNAC"
cik: "0001453687"
company_name: "Cartesian Therapeutics, Inc."
filed_at: "2024-07-02T23:59:59+00:00"
generated_at: "2026-05-31T23:44:59.532185+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Cartesian raises $130M via PIPE; Phase 2b MG trial meets primary endpoint, 71% responder rate

## Summary
- Raised ~$130M by selling 3.56M common shares and 2.94M Series B convertible preferred shares at $20 each.
- Phase 2b trial of Descartes-08 in myasthenia gravis met primary endpoint: 71% of treated patients had ≥5-point MGC improvement vs 25% placebo (p=0.018).
- Descartes-08 well tolerated with no cytokine release syndrome or neurotoxicity; supports outpatient administration without preconditioning chemo.
- Appointed Kemal Malik, MBBS to Board; first patient dosed in Phase 2 SLE trial of Descartes-08.

## SEC filing metadata
- accession: 0001140361-24-032080
- form_type: 8-K
- ticker: RNAC
- cik: 0001453687
- company_name: Cartesian Therapeutics, Inc.
- filed_at: 2024-07-02T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 5.03, 3.02, 5.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1453687/000114036124032080/0001140361-24-032080-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1453687/000114036124032080/ef20031962_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-24-032080
- JSON: https://secwatch.observer/filing/0001140361-24-032080.json
- Plain text: https://secwatch.observer/filing/0001140361-24-032080.txt

## Key facts
- Executive change
  Kemal Malik was appointed as Class II director at Cartesian Therapeutics, Inc..
  - Action: appointed
  - Role: Class II director
  source text: On July 1, 2024, the Board of Directors (the “Board”) of the Company appointed Kemal Malik, MBBS as a Class II director, and fixed the size of the Board at nine directors.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1453687/000114036124032080/0001140361-24-032080-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.